About the Book
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Pages: 121. Chapters: Stem cell treatments, Induced pluripotent stem cell, Stem cell marker, Cell therapy, Induced stem cells, Hematopoietic stem cell transplantation, Cord blood bank, Adult stem cell, Neurogenesis, Cancer stem cell, Embryonic stem cell, Neural stem cell, Benitec Biopharma, Mesenchymal stem cell, Endothelial stem cell, Bone marrow, Stem cell laws, Stem cell niche, Neuroepithelial cell, Human Stem Cells Institute, Immortal DNA strand hypothesis, Embryoid body, MIRA procedure, Geron Corporation, Clinical uses of mesenchymal stem cells, Stem cell transplantation for articular cartilage repair, Amniotic epithelial cells, Cell potency, Vet-Stem, Plant stem cell, Rex1, Human embryonic stem cells clinical trials, Amniotic stem cells, Dental pulp stem cells, Dickey-Wicker Amendment, Kenny Dies, Anthony Atala, Cardiovascular Cell Therapy Research Network, Advanced Cell Technology, Progenitor cell, Endogenous cardiac stem cell, Steve Mills (footballer), Polly and Molly, Peripheral stem cell transplantation, Stem cell laws and policy in China, SynBio, Cell bank, Cordlife, Tengion, Amniotic stem cell bank, Robert N. Klein II, Faye Armitage, List of conditions treated with hematopoietic stem cell transplantation, Gemini Somatics, CordLife (Hong Kong), Stem cell line, G 2/06, Megan and Morag, Cryo-Save, Spore-like cells, Nuclear transfer, Tetraploid complementation assay, Placenta cord banking, S1909/A2840, Stem cell theory of aging, National Center for Regenerative Medicine, Renal stem cell, Precursor cell, Stromal vascular fraction, Canadian Stem Cell Foundation, Community Blood Services, KOSR, Stem cell genomics, KSL cells, Autologous stem cell transplantation, Altered nuclear transfer, Stem cell proteomics, Stem cell chip. Excerpt: Stem-cell therapy is an intervention strategy that introduces new adult stem cells into damaged tissue in order to treat disease or injury. Many medical researchers believe that stem-cell treatments have the potential to change the face of human disease and alleviate suffering. The ability of stem cells to self-renew and give rise to subsequent generations with variable degrees of differentiation capacities, offers significant potential for generation of tissues that can potentially replace diseased and damaged areas in the body, with minimal risk of rejection and side effects. A number of stem-cell therapies exist, but most are at experimental stages or costly, with the notable exception of bone-marrow transplantation. The closer the embryo is genetically to the recipient, the less likely rejection is to occur. Use of animal embryos in humans or more commonly human embryos in lab rat models can result in transgenic cancers and additional disease transfer between species. Medical researchers anticipate that adult and embryonic stem cells will soon be able to treat cancer, Type 1 diabetes mellitus, Parkinson's disease, Huntington's disease, Celiac disease, cardiac failure, muscle damage and neurological disorders, and many others. Nevertheless, before stem-cell therapeutics can be applied in the clinical setting, more research is necessary to understand stem-cell behavior upon transplantation as well as the mechanisms of stem-cell interaction with the diseased/injured microenvironment. For over 30 years, bone-marrow, and more recently, umbilical-cord blood stem cells, have been used to treat cancer patients with conditions such as leukemia and lymphoma. During chemotherapy, most growing cells are killed by the cytotoxic agents. These agents, however, cannot discriminate between the leukaemia or neoplastic cells, and the hematopoietic stem cells within the bone marrow. It is this side effect of conventional chemotherapy strategies that the stem-cell transplant attempt
